Trevi Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Trevi Therapeutics, Inc. (TRVI) reported Basic Shares Outstanding (Weighted Average) of 156.60 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 156.60M shares, a 20.14% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 145.59M shares, a 23.79% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 145.62M shares, a 37.33% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 145.10M shares, a 43.27% increase year-over-year.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 134.75M shares, a 32.14% increase from fiscal 2024.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 101.97M shares, a 2.97% increase from fiscal 2023.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 99.03M shares, a 53.44% increase from fiscal 2022.
- Trevi Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 64.54M shares, a 182.56% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 156.60M shares 10-Q · filed 2026-08-06 | 151.13M shares 10-Q · filed 2026-08-06 | 149.27M shares derived: average of 3 quarters · filed 2026-08-06 | 148.23M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 145.59M shares 10-Q · filed 2026-05-05 | 145.61M shares derived: average of 2 quarters · filed 2026-05-05 | 145.44M shares derived: average of 3 quarters · filed 2026-05-05 | 141.67M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 145.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 145.36M shares derived: average of 2 quarters · filed 2026-03-17 | 140.36M shares derived: average of 3 quarters · filed 2026-08-06 | 134.75M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 145.10M shares 10-Q · filed 2025-11-13 | 137.73M shares derived: average of 2 quarters · filed 2026-08-06 | 131.12M shares 10-Q · filed 2025-11-13 | 124.78M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 130.35M shares 10-Q · filed 2026-08-06 | 124.02M shares 10-Q · filed 2026-08-06 | 118.00M shares derived: average of 3 quarters · filed 2026-08-06 | 113.82M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 117.61M shares 10-Q · filed 2026-05-05 | 111.82M shares derived: average of 2 quarters · filed 2026-05-05 | 108.31M shares derived: average of 3 quarters · filed 2026-05-05 | 106.49M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 106.04M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 103.66M shares derived: average of 2 quarters · filed 2026-03-17 | 102.79M shares derived: average of 3 quarters · filed 2026-03-17 | 101.97M shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 101.28M shares 10-Q · filed 2025-11-13 | 101.16M shares derived: average of 2 quarters · filed 2025-11-13 | 100.62M shares 10-Q · filed 2025-11-13 | 100.33M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 101.04M shares 10-Q · filed 2025-08-07 | 100.28M shares 10-Q · filed 2025-08-07 | 100.02M shares derived: average of 3 quarters · filed 2025-08-07 | 99.84M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 99.52M shares 10-Q · filed 2025-05-08 | 99.50M shares derived: average of 2 quarters · filed 2025-05-08 | 99.44M shares derived: average of 3 quarters · filed 2025-05-08 | 99.26M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 99.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 99.41M shares derived: average of 2 quarters · filed 2025-03-18 | 99.17M shares derived: average of 3 quarters · filed 2025-03-18 | 99.03M shares 10-K · filed 2025-03-18 |
| 2023-09-30 | 99.33M shares 10-Q · filed 2024-11-06 | 99.01M shares derived: average of 2 quarters · filed 2024-11-06 | 98.88M shares 10-Q · filed 2024-11-06 | 98.78M shares derived: average of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | 98.70M shares 10-Q · filed 2024-08-08 | 98.65M shares 10-Q · filed 2024-08-08 | 98.60M shares derived: average of 3 quarters · filed 2024-08-08 | 91.18M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 98.61M shares 10-Q · filed 2024-05-07 | 98.56M shares derived: average of 2 quarters · filed 2024-05-07 | 88.67M shares derived: average of 3 quarters · filed 2024-05-07 | 81.39M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 98.50M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | 83.70M shares derived: average of 2 quarters · filed 2024-03-20 | 75.65M shares derived: average of 3 quarters · filed 2024-03-20 | 64.54M shares 10-K · filed 2024-03-20 |
| 2022-09-30 | 68.90M shares 10-Q · filed 2023-11-09 | 64.22M shares derived: average of 2 quarters · filed 2023-11-09 | 53.22M shares 10-Q · filed 2023-11-09 | 47.36M shares derived: average of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | 59.54M shares 10-Q · filed 2023-08-10 | 45.25M shares 10-Q · filed 2023-08-10 | 40.18M shares derived: average of 3 quarters · filed 2023-08-10 | 35.54M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 30.81M shares 10-Q · filed 2023-05-11 | 30.50M shares derived: average of 2 quarters · filed 2023-05-11 | 27.54M shares derived: average of 3 quarters · filed 2023-05-11 | 25.68M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 30.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 25.90M shares derived: average of 2 quarters · filed 2023-03-16 | 23.97M shares derived: average of 3 quarters · filed 2023-03-16 | 22.84M shares 10-K · filed 2023-03-16 |
| 2021-09-30 | 21.61M shares 10-Q · filed 2022-11-10 | 20.87M shares derived: average of 2 quarters · filed 2022-11-10 | 20.39M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 20.12M shares 10-Q · filed 2022-08-11 | 19.77M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |